NEW YORK (Reuters) - The newly empowered Democrats’ vow to cut healthcare costs might spell bad news for the brand-name pharmaceutical industry, but could provide new momentum for generic drug rivals, the Wall Street Journal reported on its Web site on Tuesday.>>> Discuss This Story
